Chemo-enzymatic synthesis of 2'-O-methoxyethyl ribonucleosides using a phosphodiesterase from Serratia marcescens

Applied Microbiology and Biotechnology
Guy Marais, Oreste Ghisalba

Abstract

An enzyme able to cleave the 3',5'-phosphate ring of 2'-methoxyethyl cyclic nucleotides (3',5'-cyclic nucleotide phosphodiesterase, EC 3.1.4.17) from Serratia marcescens DSM 30121 was used to deprotect the cyclic phosphate nucleotides after chemical alkylation. The process yielded 2'-O-alkylated nucleosides used as building blocks of antisense oligonucleotides for subsequent potential applications in therapeutics (antisense oligonucleotide synthesis) and diagnostics. The phosphodiesterase from the Gram-negative enteric bacterium S. marcescens was selected on account of the broad substrate range and high activity of the enzyme. The protein was purified by heat-treatment of the crude cell-free extract, followed by column chromatography (gel filtration). It was characterised and showed optimal activity at a broad pH range (pH 6.8-9.4, with a peak at ca. pH 8.5) and at a temperature of 60-65 degrees C. No metal ions were required for activity, although Ba2+ was an activator. Conversion of 2'-O-methoxyethyl cAMP into the corresponding nucleoside derivative on a multi-gram scale was successfully performed in two steps, using the S. marcescens enzyme in conjunction with a commercially available alkaline phosphatase from Escherichia coli.

References

Jan 1, 1990·Methods in Enzymology·S Englard, S Seifter
Oct 14, 1970·Biochimica Et Biophysica Acta·T Okabayashi, M Ide
Dec 19, 1972·Biochemistry·I TazawaP O Ts'o
Dec 24, 1996·Proceedings of the National Academy of Sciences of the United States of America·B P MoniaD Fabbro
Jun 1, 1997·Antisense & Nucleic Acid Drug Development·N M Dean, R H Griffey

❮ Previous
Next ❯

Citations

Aug 20, 2008·Nucleosides, Nucleotides & Nucleic Acids·Shabbir Ali S TajVasulinga T Ravikumar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.